Practice of venom immunotherapy in the United Kingdom: A national audit and review of literature

Clinical and Experimental Allergy

Volumn 38, Issue 10, 2008, Pages 1651-1658

  Diwakar, L ^a   Noorani, S ^a   Huissoon, A P ^a   Frew, A J ^b   Krishna, M T ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b BRIGHTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Current UK practice; Hymenoptera allergy; National audit; RAST tests; Skin tests; Venom immunotherapy

Indexed keywords

ANTIHISTAMINIC AGENT; BEE VENOM; IMMUNOGLOBULIN E; TRYPTASE; WASP VENOM;

ARTICLE; DESENSITIZATION; HUMAN; IMMUNOTHERAPY; INSECT ALLERGY; INSECT STING; MEDICAL LITERATURE; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SKIN TEST; UNITED KINGDOM;

ANIMALS; BEE VENOMS; GREAT BRITAIN; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOTHERAPY; MEDICAL AUDIT; QUESTIONNAIRES; SKIN TESTS; WASP VENOMS;

EID: 53749094692     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2008.03044.x     Document Type: Article

References (47)

1. Moffitt JE, Golden DB, Reisman RE et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol 2004 114 : 869 86.
2. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000 30 : 1144 50.
3. Fernandez J. Distribution of vespid species in Europe. Curr Opin Allergy Clin Immunol 2004 4 : 319 24.
4. Golden DB, Schwartz HJ. Guidelines for venom immunotherapy. J Allergy Clin Immunol 1986 77 : 727 8.
5. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998 351 : 1225 32.
6. Holgate ST, Ewan P et al. Allergy - an unmet need. Royal College of Physicians Working Party: working party on the provision of allergy services in the UK, June 2003.
7. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN. Diagnosis of Hymenoptera venom allergy. Allergy 2005 60 : 1339 49.
8. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005 60 : 1459 70.
9. Mueller HL. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966 3 : 331 3.
10. Goldberg A, Confino-Cohen R. Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. J Allergy Clin Immunol 1997 100 : 182 4.
11. Hunt KJ, Valentine MD, Sobotka AK, Lichtenstein LM. Diagnosis of allergy to stinging insects by skin testing with Hymenoptera venoms. Ann Intern Med 1976 85 : 56 9.
12. Reisman RE. Insect sting allergy: the dilemma of the negative skin test reactor. J Allergy Clin Immunol 2001 107 : 781 2.
13. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol 2001 107 : 897 901.
14. Lerch E, Muller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998 101 : 606 12.
15. Ebo DG, Hagendorens MM, Bridts CH, De Clerck LS, Stevens WJ. Hymenoptera venom allergy: taking the sting out of difficult cases. J Investig Allergol Clin Immunol 2007 17 : 357 60.
16. Sturm GJ, Bohm E, Trummer M, Weiglhofer I, Heinemann A, Aberer W. The CD63 basophil activation test in Hymenoptera venom allergy: a prospective study. Allergy 2004 59 : 1110 7.
17. Sainte-Laudy J, Sabbah A, Drouet M, Lauret MG, Loiry M. Diagnosis of venom allergy by flow cytometry. Correlation with clinical history, skin tests, specific IgE, histamine and leukotriene C4 release. Clin Exp Allergy 2000 30 : 1166 71.
18. Straumann F, Bucher C, Wuthrich B. Double sensitization to honeybee and wasp venom: immunotherapy with one or with both venoms? Value of FEIA inhibition for the identification of the cross-reacting IgE antibodies in double-sensitized patients to honeybee and wasp venom. Int Arch Allergy Immunol 2000 123 : 268 74.
19. Caruso B, Bonadonna P, Severino MG et al. Evaluation of the IgE cross-reactions among vespid venoms. A possible approach for the choice of immunotherapy. Allergy 2007 62 : 561 4.
20. Bousquet J, Muller UR, Dreborg S et al. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology. Allergy 1987 42 : 401 13.
21. Egner W, Ward C, Brown DL, Ewan PW. The frequency and clinical significance of specific IgE to both wasp (Vespula) and honey-bee (Apis) venoms in the same patient. Clin Exp Allergy 1998 28 : 26 34.
22. Dubois AE. Mastocytosis and Hymenoptera allergy. Curr Opin Allergy Clin Immunol 2004 4 : 291 5.
23. Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003 33 : 1216 20.
24. Ludolph-Hauser D, Rueff F, Fries C, Schopf P, Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001 357 : 361 2.
25. Bonadonna P, Zanotti R, Caruso B et al. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol 2008 121 : 256 7.
26. de Olano DG, Alvarez-Twose I, Esteban-Lopez MI et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008 121 : 519 26.
27. Golden DB, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980 92 : 620 4.
28. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC. The Hymenoptera venom study. III: safety of venom immunotherapy. J Allergy Clin Immunol 1990 86 : 775 80.
29. Wyss M, Scheitlin T, Stadler BM, Wuthrich B. Immunotherapy with aluminum hydroxide adsorbed insect venom extracts (Alutard SQ): immunologic and clinical results of a prospective study over 3 years. Allergy 1993 48 : 81 6.
30. Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993 23 : 226 30.
31. Gillman SA, Cummins LH, Kozak PP Jr., Hoffman DR. Venom immunotherapy: comparison of "rush" vs "conventional" schedules. Ann Allergy 1980 45 : 351 4.
32. Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994 73 : 423 8.
33. Brehler R, Wolf H, Kutting B, Schnitker J, Luger T. Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000 105 (6 Pt 1) : 1231 5.
34. Mosbech H, Muller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy 2000 55 : 1005 10.
35. Jutel M, Blaser K, Akdis CA. Histamine receptors in immune regulation and allergen-specific immunotherapy. Immunol Allergy Clin North Am 2006 26 : 245 59, vii.
36. Brockow K, Kiehn M, Riethmuller C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1997 100 : 458 63.
37. Muller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001 107 : 81 6.
38. Munakata Y, Umezawa Y, Iwata S et al. Specific inhibition of TH2-type cytokine production from human peripheral T cells by terfenadine in vitro. Clin Exp Allergy 1999 29 : 1281 6.
39. Graft DF. Maintenance venom immunotherapy. Curr Opin Allergy Clin Immunol 2002 2 : 359 62.
40. Goldberg A, Confino-Cohen R. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious. J Allergy Clin Immunol 2001 107 : 902 6.
41. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001 108 : 1027 32.
42. Rueff F, Przybilla B. Venom immunotherapy: adverse reactions and treatment failure. Curr Opin Allergy Clin Immunol 2004 4 : 307 11.
43. Golden DB, Addison BI, Gadde J, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Prospective observations on stopping prolonged venom immunotherapy. J Allergy Clin Immunol 1989 84 : 162 7.
44. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996 97 : 579 87.
45. Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000 105 (2 Pt 1) : 385 90.
46. Golden DB. Discontinuing venom immunotherapy. Curr Opin Allergy Clin Immunol 2001 1 : 353 6.
47. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004 351 : 668 74.